Literature DB >> 16287793

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Masahide Hamaguchi1, Takao Kojima, Noriyuki Takeda, Takayuki Nakagawa, Hiroya Taniguchi, Kota Fujii, Tatsushi Omatsu, Tomoaki Nakajima, Hiroshi Sarui, Makoto Shimazaki, Takahiro Kato, Junichi Okuda, Kazunori Ida.   

Abstract

BACKGROUND: The frequent association of nonalcoholic fatty liver disease with components of the metabolic syndrome such as obesity, hyperglycemia, dyslipidemia, and hypertension is well known. However, no prospective study has examined the role of the metabolic syndrome in the development of this disease.
OBJECTIVE: To characterize the longitudinal relationship between the metabolic syndrome and nonalcoholic fatty liver disease.
DESIGN: A prospective observational study.
SETTING: A medical health checkup program in a general hospital. PARTICIPANTS: 4401 apparently healthy Japanese men and women, 21 to 80 years of age, with a mean body mass index (BMI) of 22.6 kg/m2 (SD, 3.0). MEASUREMENTS: Alcohol intake was assessed by using a questionnaire. Biochemical tests for liver and metabolic function and abdominal ultrasonography were done. Modified criteria of the National Cholesterol Education Program Adult Treatment Panel III were used to characterize the metabolic syndrome.
RESULTS: At baseline, 812 of 4401 (18%) participants had nonalcoholic fatty liver disease. During the mean follow-up period of 414 days (SD, 128), the authors observed 308 new cases (10%) of nonalcoholic fatty liver disease among 3147 participants who were disease-free at baseline and who completed a second examination. Regression of nonalcoholic fatty liver disease was found in 113 (16%) of 704 participants who had the disease at baseline and who completed a second examination. Men and women who met the criteria for the metabolic syndrome at baseline were more likely to develop the disease during follow-up (adjusted odds ratio, 4.00 [95% CI, 2.63 to 6.08] and 11.20 [CI, 4.85 to 25.87], respectively). Nonalcoholic fatty liver disease was less likely to regress in those participants with the metabolic syndrome at baseline. LIMITATIONS: Ultrasonography may lead to an incorrect diagnosis of nonalcoholic fatty liver disease in 10% to 30% of cases and cannot distinguish steatohepatitis from simple steatosis. Self-reported alcohol intake may cause bias. Because all of the participants were Japanese, generalizability to non-Japanese populations is uncertain.
CONCLUSIONS: The metabolic syndrome is a strong predictor of nonalcoholic fatty liver disease.

Entities:  

Mesh:

Year:  2005        PMID: 16287793     DOI: 10.7326/0003-4819-143-10-200511150-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  314 in total

1.  Plasma free myristic acid proportion is a predictor of nonalcoholic steatohepatitis.

Authors:  Kengo Tomita; Toshiaki Teratani; Hirokazu Yokoyama; Takahiro Suzuki; Rie Irie; Hirotoshi Ebinuma; Hidetsugu Saito; Ryota Hokari; Soichiro Miura; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2011-04-23       Impact factor: 3.199

2.  Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Mitsuhito Koizumi; Shinya Furukawa; Teruhisa Ueda; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

3.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

4.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 5.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

6.  The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial.

Authors:  William W Shields; K E Thompson; G A Grice; S A Harrison; W J Coyle
Journal:  Therap Adv Gastroenterol       Date:  2009-05       Impact factor: 4.409

7.  Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study.

Authors:  Elizabeth K Speliotes; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; James B Meigs; Dushyant V Sahani; Joel N Hirschhorn; Christopher J O'Donnell; Caroline S Fox
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

Review 8.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

Review 9.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

10.  Synergistic effect of fatty liver and smoking on metabolic syndrome.

Authors:  Po-Hsin Chiang; Tsui-Yen Chang; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.